The public health toll from bereavement is well-documented in the medical literature, with bereaved persons at greater risk for many adverse outcomes, including mental health challenges, decreased quality of life, health care neglect, cancer, heart disease, suicide, and death.
Avidity’s $300M offering; Rapport raises $174M
Plus, news about Replimmune, Novo Nordisk and Biosplice: Avidity Biosciences is looking for $300M in stock sale: The RNA company is planning a $300 million
June 14, 2024